## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (Case No. 02-274-A)

In re Application of: Narhi et al.	PATENT )
Serial No.: Unassigned	) Before the Examiner: Unassigned
Filed: September 199, 2003	) ) Group Art Unit: Unassigned )
For: Keratinocyte Growth Factor-2	, )
Products	ý e e e e e e e e e e e e e e e e e e e
Commissioner for Patents	
P.O. Box 1450	
Alexandria, VA 22313-1450	

Sir:

## **INFORMATION DISCLOSURE STATEMENT**

This statement is filed under 37 C.F.R. §§ 1.97-1.98 in compliance with the duty of disclosure set forth in 37 C.F.R. § 1.56. Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents. Applicants further reserve the right to take appropriate action to establish the patentability of the claimed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, Applicants hereby authorize the Commissioner to charge the fee to Deposit Account No. 13-2490.

Respectfully submitted,

McDonnell Boehnen Hulbert & Berghoff

By: Malda. Consider the Donald L. Zuhn, Ph.D. Reg. No. 48,710

Dated: September 19, 2003

Substitute for form 1449A/PTO			Complete if Known		
		Application No.			
1 11	NFORMATION DIS	CLC	Filing Date:	09-19-2003	
- ·	TATEMENT BY A		First Named Inventor	Narhi	
	MAILMENT BI A.	. –	Group Art Unit		
	(use as many sheets as n	ecessa	Examiner Name		
Sheet	1	of	1	Attorney Docket No.	02-274-A

U.S. PATENT DOCUMENTS							
Examiner   Cite   No.1	U.S. Patent (	Document	Name of Patentee or Applicant of	Date of Publication of	Pages, Columns, Lines		
	No.¹	Number	Kind Code <sup>2</sup> (if known)	Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Figures Appear	
		6,077,692		Ruben et al.	06-20-2000		
		6,238,888	B1	Gentz et al.	05-29-2001		

FOREIGN PATENT DOCUMENTS								
Examiner	l la	Pages, Columns, Lines						
Initials* N		Office <sup>3</sup>	Number⁴		Applicant of Cited		Where Relevant Passages or Figures Appear	T <sup>6</sup>

OTHER DOCUMENTS NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>	
			Ţ	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English translation is attached.